|
30 Jan 2020 |
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
|
|
30 Jan 2020 |
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
|
|
30 Jan 2020 |
European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
|
|
30 Jan 2020 |
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
|
|
29 Jan 2020 |
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
|
|
29 Jan 2020 |
Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
|
|
27 Jan 2020 |
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123
|
|
25 Jan 2020 |
Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
|
|
25 Jan 2020 |
Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens™
|
|
25 Jan 2020 |
Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV
|
|
22 Jan 2020 |
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
|
|
22 Jan 2020 |
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
|
|
22 Jan 2020 |
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
|
|
22 Jan 2020 |
PDC*line Pharma raises €20 million in Series B financing round
|
|
21 Jan 2020 |
Biotech start-up Seekyo raises €800k with leverage from French Tech Seed Fund
|
|
17 Jan 2020 |
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
|
|
17 Jan 2020 |
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
|
|
15 Jan 2020 |
Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
|
|
15 Jan 2020 |
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
|
|
15 Jan 2020 |
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
|
|
14 Jan 2020 |
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
|
|
13 Jan 2020 |
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
|
|
13 Jan 2020 |
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
|
|
13 Jan 2020 |
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
|
|
13 Jan 2020 |
BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy
|
